Table 2 Clinical and biological characteristics of patients at inclusion in the study
Female, n (%)27 (54)
Age at diagnosis, median (IQR)26 (20–35)
Disease duration (years), median (IQR)6 (2–11)
Disease location
    Ileal, n (%)11 (22)
    Ileocolonic, n (%)24 (48)
    Colonic, n (%)15 (30)
    Associated upper GI lesions5 (10)
Perianal involvement, n (%)12 (24)
Harvey–Bradshaw index, median (IQR)7 (3–11)
Harvey–Bradshaw index >4, n (%)35 (70)
Previous surgery, n (%)15 (30)
Concomitant treatments
    5-ASA, n (%)10 (20)
    Steroids, n (%)16 (32)
    Immunosuppressants, n (%)24 (48)
    Anti-TNF antibodies, n (%)5 (10)
CRP (mg/l), median (IQR)19.5 (5.0–77.5)
CDEIS, median (IQR)6.68 (2.47–13.98)
CDEIS <3.5/3.5–7/>7, n (%)13 (26)/12 (24)/25 (50)
  • 5-ASA, 5-acetylsalicylic acid; CDEIS, Crohn’s Disease Endoscopic Index of Severity; CRP, C-reactive protein; GI, gastrointestinal; IQR, interquartile range; TNF, tumour necrosis factor.